UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer

British journal of cancer, 2013-12, Vol.109 (12), p.3067-3072

2013

Volltextzugriff (PDF)

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

Annals of oncology, 2019-07, Vol.30 (7), p.1088-1095

2019

Volltextzugriff (PDF)

International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic

Radiotherapy and oncology, 2020-07, Vol.148, p.213-215

2020

Volltextzugriff (PDF)

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC

British journal of cancer, 2014-01, Vol.110 (2), p.363-368

2014

Volltextzugriff (PDF)

The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy

Colorectal disease, 2009-03, Vol.11 (3), p.264-269

2009

Volltextzugriff (PDF)

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer

Annals of oncology, 2010-03, Vol.21 (3), p.535-539

2010

Volltextzugriff (PDF)

The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer

Colorectal disease, 2011-09, Vol.13 (9), p.984-988

2011

Volltextzugriff (PDF)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

British journal of cancer, 2014-12, Vol.111 (12), p.2380-2380

2014

Volltextzugriff (PDF)

A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)

JOURNAL OF CLINICAL ONCOLOGY, 2011, Vol.29 (15_suppl), p.3526-3526

2011

Volltextzugriff (PDF)

Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer

Physics and imaging in radiation oncology, 2024-07, Vol.31, p.100634, Article 100634

2024

Volltextzugriff (PDF)

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Annals of oncology, 2013-09, Vol.24 (9), p.2335-2341

2013

Volltextzugriff (PDF)

Cell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii186

2018

Volltextzugriff (PDF)

The predictive value of KRAS and BRAF mutations for outcome in second-line irinotecan monotherapy in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14062-e14062

2010

Volltextzugriff (PDF)

Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

Annals of oncology, 2018-10, Vol.29, p.viii241-viii242

2018

Volltextzugriff (PDF)

556PCell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Cell-free DNA , KRAS , and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3599-3599

2011

Volltextzugriff (PDF)

Treatment related changes of the serum epidermal growth factor receptor in advanced colorectal cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e22096-e22096

2009

Volltextzugriff (PDF)

The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3600-3600

2011

Volltextzugriff (PDF)

715PClinical utility of plasma cell-free DNA in patients with pancreatic cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

The prognostic value of EGFR Sp1–216 gene polymorphism in locally advanced rectal cancer treated with preoperative chemoradiation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4123-4123

2008

Volltextzugriff (PDF)

An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3528-3528

2011

Volltextzugriff (PDF)

Functional and prognostic influence of receptor polymorphisms in the vascular endothelial growth factor system in colorectal cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e15032-e15032

2009

Volltextzugriff (PDF)

P-007Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patients

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii2-ii3

2016

Volltextzugriff (PDF)

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

Annals of oncology, 2019-07, Vol.30 (7), p.1088

2019

Volltextzugriff (PDF)

The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer: Relationship between serum VEGF-A and MSI

Colorectal disease, 2011-09, Vol.13 (9), p.984-988

2011

Volltextzugriff (PDF)

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(297)
Mit Volltextzugriff
(280)

Publikationsform

Sprache

Englisch
(311)
Deutsch
(11)
Schwedisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC

The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer

The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)

Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Cell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases

The predictive value of KRAS and BRAF mutations for outcome in second-line irinotecan monotherapy in metastatic colorectal cancer (mCRC)

Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

556PCell free DNA and hepatic arterial infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases

Cell-free DNA , KRAS , and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan

Treatment related changes of the serum epidermal growth factor receptor in advanced colorectal cancer

The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study

715PClinical utility of plasma cell-free DNA in patients with pancreatic cancer

The prognostic value of EGFR Sp1–216 gene polymorphism in locally advanced rectal cancer treated with preoperative chemoradiation

An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy

Functional and prognostic influence of receptor polymorphisms in the vascular endothelial growth factor system in colorectal cancer

P-007Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patients

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer: Relationship between serum VEGF-A and MSI

Suchergebnisse filtern